- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04772989
A Study to Evaluate AB308 in Combination With AB122 in Participants With Advanced Malignancies (ARC-12)
A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB308 in Combination With AB122 in Participants With Advanced Malignancies
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Contact
- Name: Medical Director
- Phone Number: +1-510-462-3330
- Email: ClinicalTrials@arcusbio.com
Study Locations
-
-
-
Kraków, Poland
- Jagiellonskie Centrum Innowacji
-
Lubin, Poland
- Specjalistyczna Praktyka Lekarska Slawomir Mandziuk
-
Olsztyn, Poland
- SPZOZ MiSWiA z Warminsko-Mazurskim Centrum Onkologii w Olsztynie
-
Poznań, Poland
- Med-Polonia Sp. z o.o.
-
Warszawa, Poland
- Narodowy Instytut Onkologii
-
-
-
-
-
Barcelona, Spain
- Hospital Universitario Vall d'Hebron
-
Madrid, Spain
- Clinica Universidad de Navarra
-
Madrid, Spain
- START MADRID_Hospital Universitario HM Sanchinarro - CIOCC
-
-
-
-
Arizona
-
Phoenix, Arizona, United States, 85054-4502
- Mayo Clinic Arizona - Mayo Clinic Hospital
-
-
California
-
Los Angeles, California, United States, 90095
- University of California, Los Angeles
-
-
Colorado
-
Aurora, Colorado, United States, 80045-2545
- University of Colorado - Cancer Center - PPDS
-
-
Florida
-
Jacksonville, Florida, United States, 32224
- Mayo Clinic Jacksonville - PPDS
-
Orlando, Florida, United States, 43210
- AdventHealth Orlando
-
-
Georgia
-
Augusta, Georgia, United States, 30909-6520
- Augusta Oncology Associates - Wheeler Road
-
-
Indiana
-
Goshen, Indiana, United States, 46526
- Goshen Health System
-
-
Iowa
-
Iowa City, Iowa, United States, 52242
- Holden Comprehensive Cancer Center
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- Norton Cancer Institute-Downtown
-
-
Michigan
-
Novi, Michigan, United States, 48377
- Henry Ford Health System
-
-
Minnesota
-
Rochester, Minnesota, United States, 55905
- Mayo Clinic - PPDS
-
-
New York
-
New York, New York, United States, 10032-3729
- Columbia University Medical Center
-
-
Ohio
-
Canton, Ohio, United States, 44718
- Gabrail Cancer Center
-
Columbus, Ohio, United States, 43210
- Ohio State University
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- University of Oklahoma Peggy and Charles Stephenson Cancer Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, United States, 15240
- University of Pittsburgh Medical Center
-
-
Tennessee
-
Nashville, Tennessee, United States, 37205
- Tennessee Onocology - Nashville
-
-
Texas
-
San Antonio, Texas, United States, 78229
- START South Texas Accelerated Research Therapeutics - San Antonio
-
-
Utah
-
West Valley City, Utah, United States, 84119
- START South Texas Accelerated Research Therapeutics - Mountain Region
-
-
Virginia
-
Fairfax, Virginia, United States, 22033-1712
- Virginia Cancer Specialists
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
- University of Wisconsin - Madison
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
- Male or female participants ≥ 18 years of age (or age ≥ regionally approved age of consent for participation in investigational clinical studies) at the time of signing the informed consent.
- Contraceptive use by men and women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.
- Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1
- Adequate organ and marrow function
Exclusion Criteria:
- History of trauma or major surgery within 28 days prior to the first dose of study treatment.
- Prior treatment with an anti-TIGIT antibody.
- Any active or prior autoimmune disease that required treatment within 3 years of the first dose of study treatment.
- Prior chemotherapy, targeted small-molecule therapy, immunotherapy, or biologic agents, or use of other investigational drugs within 28 days before first dose of study treatment.
- Discontinued prior immunotherapy for immune related adverse events with a high severity.
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dose Escalation Q3W Cohorts
Escalating doses of AB308 in combination with zimberelimab (360 mg) will be given every 3 weeks in participants with advanced malignancies.
|
Administered intravenously (IV) as specified in the treatment arm
Administered IV as specified in the treatment arm
Other Names:
|
Experimental: Dose Escalation Q4W Cohorts
Escalating doses of AB308 in combination with zimberelimab (480 mg) will be given every 4 weeks in participants with advanced malignancies.
|
Administered intravenously (IV) as specified in the treatment arm
Administered IV as specified in the treatment arm
Other Names:
|
Experimental: Dose Escalation Q6W Cohort
Selected dose of AB308 in combination with zimberelimab will be given every 6 weeks in participants with advanced malignancies.
|
Administered intravenously (IV) as specified in the treatment arm
Administered IV as specified in the treatment arm
Other Names:
|
Experimental: Dose Expansion Cohort 1
AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with in participants with locally advanced or metastatic NSCLC.
|
Administered intravenously (IV) as specified in the treatment arm
Administered IV as specified in the treatment arm
Other Names:
|
Experimental: Dose Expansion Cohort 2
AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with melanoma.
|
Administered intravenously (IV) as specified in the treatment arm
Administered IV as specified in the treatment arm
Other Names:
|
Experimental: Dose Expansion Cohort 3
AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with metastatic gastric, or gastroesophageal junction, or esophageal cancer.
|
Administered intravenously (IV) as specified in the treatment arm
Administered IV as specified in the treatment arm
Other Names:
|
Experimental: Dose Expansion Cohort 4
AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with cervical cancer.
|
Administered intravenously (IV) as specified in the treatment arm
Administered IV as specified in the treatment arm
Other Names:
|
Experimental: Dose Expansion Cohort 5
AB308 will be given in combination with zimberelimab at 360 mg or 480 mg Q3W or Q4W, respectively, in participants with hematological malignancies.
|
Administered intravenously (IV) as specified in the treatment arm
Administered IV as specified in the treatment arm
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of participants with Adverse Events
Time Frame: From first study treatment administration until up to 90 days after the last dose (Approximately 1 year)
|
From first study treatment administration until up to 90 days after the last dose (Approximately 1 year)
|
Percentage of participants who experience a Dose Limiting Toxicity
Time Frame: From first study treatment administration through Day 21 (Q3W arm) or Day 28 (Q4W arm) or Day 42 (Q6W arm)
|
From first study treatment administration through Day 21 (Q3W arm) or Day 28 (Q4W arm) or Day 42 (Q6W arm)
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Duration of Response
Time Frame: From the date of first occurrence of a documented objective response to first documentation of disease progression or death from any cause, whichever occurs first (up to approximately 3-5 years)
|
From the date of first occurrence of a documented objective response to first documentation of disease progression or death from any cause, whichever occurs first (up to approximately 3-5 years)
|
Percentage of Participants with Disease Control (complete response, partial response, or stable disease) for >6 months
Time Frame: From study enrollment until disease progression or loss of clinical benefit (up to approximately 3-5 years)
|
From study enrollment until disease progression or loss of clinical benefit (up to approximately 3-5 years)
|
Percentage of participants with Objective Response
Time Frame: From study enrollment until participant discontinuation, first occurrence of progressive disease, or death from any cause, whichever occurs first (up to approximately 3-5 years)
|
From study enrollment until participant discontinuation, first occurrence of progressive disease, or death from any cause, whichever occurs first (up to approximately 3-5 years)
|
Serum concentration of AB308
Time Frame: Recorded at baseline (day 1 of cycle 1), during each of the first 5 cycles (each cycle is 21 days or 28 days or 42 days) and up to the first 16 cycles of treatment (up to 22 months), and 30 and 90 days post last dose (up to approximately 25 months)
|
Recorded at baseline (day 1 of cycle 1), during each of the first 5 cycles (each cycle is 21 days or 28 days or 42 days) and up to the first 16 cycles of treatment (up to 22 months), and 30 and 90 days post last dose (up to approximately 25 months)
|
Serum concentration of zimberelimab
Time Frame: Recorded at baseline (day 1 of cycle 1), during each of the first 5 cycles (each cycle is 21 days or 28 days or 42 days) and up to the first 16 cycles of treatment (up to 22 months), and 30 and 90 days post last dose (up to approximately 25 months)
|
Recorded at baseline (day 1 of cycle 1), during each of the first 5 cycles (each cycle is 21 days or 28 days or 42 days) and up to the first 16 cycles of treatment (up to 22 months), and 30 and 90 days post last dose (up to approximately 25 months)
|
Percentage of participants with anti-drug antibodies to AB308
Time Frame: Recorded at baseline (day 1 of cycle 1), during each of the first 5 cycles (each cycle is 21 days or 28 days or 42 days) and up to the first 16 cycles of treatment (up to 22 months), and 30 and 90 days post last dose (up to approximately 25 months)
|
Recorded at baseline (day 1 of cycle 1), during each of the first 5 cycles (each cycle is 21 days or 28 days or 42 days) and up to the first 16 cycles of treatment (up to 22 months), and 30 and 90 days post last dose (up to approximately 25 months)
|
Percentage of participants with anti-drug antibodies to zimberelimab
Time Frame: Recorded at baseline (day 1 of cycle 1), during each of the first 5 cycles (each cycle is 21 days or 28 days or 42 days) and up to the first 16 cycles of treatment (up to 22 months), and 30 and 90 days post last dose (up to approximately 25 months)
|
Recorded at baseline (day 1 of cycle 1), during each of the first 5 cycles (each cycle is 21 days or 28 days or 42 days) and up to the first 16 cycles of treatment (up to 22 months), and 30 and 90 days post last dose (up to approximately 25 months)
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Medical Director, Arcus Biosciences
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Cardiovascular Diseases
- Vascular Diseases
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Hematologic Diseases
- Hemorrhagic Disorders
- Hemostatic Disorders
- Paraproteinemias
- Blood Protein Disorders
- Neoplasms, Plasma Cell
- Lymphoma, B-Cell
- Lymphoma
- Lymphoma, Large B-Cell, Diffuse
- Multiple Myeloma
- Lymphoma, Non-Hodgkin
Other Study ID Numbers
- ARC-12
- 2021-005589-16 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Arcus will provide access to individual de-identified participant data and related study documents (e.g., protocol, Statistical Analysis Plan [SAP], Clinical Study Report [CSR]) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions.
For more information, please visit our website.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Melanoma
-
H. Lee Moffitt Cancer Center and Research InstituteTurnstone Biologics, Corp.RecruitingMetastatic Melanoma | Conjunctival Melanoma | Ocular Melanoma | Unresectable Melanoma | Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Iris Melanoma | Acral Melanoma | Non-Cutaneous MelanomaUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Mucosal Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Ciliary Body and Choroid Melanoma, Small Size | Iris Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage... and other conditionsUnited States
-
National Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IA Melanoma | Stage IB Melanoma | Stage IIA MelanomaUnited States
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); University of VirginiaCompletedStage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage III Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IA Skin Melanoma | Stage IB Skin Melanoma | Stage 0 Skin Melanoma | Stage I Skin Melanoma | Stage II Skin MelanomaUnited States
-
MelanomaPRO, RussiaRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma, Stage II | Melanoma, Uveal | Melanoma in Situ | Melanoma, OcularRussian Federation
-
National Cancer Institute (NCI)CompletedStage IV Melanoma | Ciliary Body and Choroid Melanoma, Medium/Large Size | Iris Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIB Melanoma | Stage IIC MelanomaUnited States
-
Mayo ClinicNational Cancer Institute (NCI)CompletedRecurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Stage IIB Melanoma | Stage IIC Melanoma | Stage IIA MelanomaUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); National Comprehensive Cancer NetworkTerminatedRecurrent Melanoma | Stage IV Melanoma | Metastatic Intraocular Melanoma | Recurrent Intraocular Melanoma | Stage IV Intraocular Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC Melanoma | Extraocular Extension Melanoma | Stage IIIA Intraocular Melanoma | Stage IIIB Intraocular Melanoma | Stage...United States
-
Emory UniversityGenentech, Inc.Active, not recruitingStage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Unresectable Melanoma | Stage III Melanoma | Stage IIIA Skin Melanoma | Cutaneous Melanoma, Stage III | Cutaneous Melanoma, Stage IVUnited States
-
BiocadRecruitingMelanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma Metastatic | Melanoma Unresectable | Melanoma AdvancedIndia, Russian Federation, Belarus